Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 15/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 13/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304094 | 1.00 | OPRL1 (0.53) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL305263 | 0.88 | OPRM1 (0.39) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL580033 | 0.88 | OPRM1 (0.39) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL305262 | 0.88 | OPRM1 (0.39) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2629517 | 0.72 | OPRM1 (0.70) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12702339 | 0.69 | OPRK1 (0.56) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL24422207 | 0.68 | OPRM1 (0.59) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL26239089 | 0.68 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL304322 | 0.68 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL2778830 | 0.68 | OPRL1 (0.72) | OPRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-27 | — | — | US | disclosed |
| US-9018390-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-28 | — | — | US | disclosed |
| US-9006455-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-8822444-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8809548-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-19 | — | — | US | disclosed |
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-31 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-7741347-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | OPRL1 4222/4885OPRM1 2703/4885OPRK1 2874/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | OPRL1 4510/4885OPRM1 3204/4885OPRK1 3631/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20130317213-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | OPRL1 4332/4885OPRM1 2615/4885OPRK1 2572/4885 |
| US-20110077280-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | OPRL1 4222/4885OPRM1 2703/4885OPRK1 2874/4885 |
| US-20110268697-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | OPRL1 4332/4885OPRM1 2615/4885OPRK1 2572/4885 |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | OPRL1 4222/4885OPRM1 2703/4885OPRK1 2874/4885 |
| US-20160311778-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20130280211-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | OPRL1 4100/4885OPRM1 2169/4885OPRK1 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.